A detailed history of State Street Corp transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 59,007 shares of ELYM stock, worth $293,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,007
Previous 21,700 171.92%
Holding current value
$293,854
Previous $59,000 610.17%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.6 - $10.2 $96,998 - $380,531
37,307 Added 171.92%
59,007 $419,000
Q3 2023

Nov 14, 2023

BUY
$2.48 - $3.15 $4,712 - $5,985
1,900 Added 9.6%
21,700 $57,000
Q2 2022

Aug 15, 2022

SELL
$2.77 - $8.4 $208,497 - $632,268
-75,270 Reduced 79.17%
19,800 $60,000
Q1 2022

May 16, 2022

BUY
$8.01 - $13.15 $15,947 - $26,181
1,991 Added 2.14%
95,070 $798,000
Q4 2021

Feb 14, 2022

BUY
$8.61 - $20.47 $60,080 - $142,839
6,978 Added 8.1%
93,079 $974,000
Q3 2021

Nov 15, 2021

BUY
$14.45 - $28.61 $1.24 Million - $2.46 Million
86,101 New
86,101 $1.55 Million

Others Institutions Holding ELYM

About Eliem Therapeutics, Inc.


  • Ticker ELYM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,567,700
  • Market Cap $132M
  • Description
  • Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...
More about ELYM
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.